The spinal cord is made up of millions of nerve cells that send projections up and down the cord and out into other parts of the body. The information that allows us to sit, run, go to the toilet and breathe travels along these projections, called nerves. Whenever the hard vertebrae of the spinal column that protect the spinal cord are broken or dislocated, the nerves in the spinal cord are damaged, and cells may die. Cells of the spinal cord that are lost cannot be replaced by the body. Consequently, the function of the spinal cord becomes impaired, and patients may end up with severe movement and sensation disabilities.
NINDS information on spinal cord injury
Stem cells hold potential for treating spinal cord injuries. Based on the findings from a large number of animal studies, scientists are working on the ways that stem cells may contribute to spinal cord repair:

In December 2010 the Swiss regulatory agency for therapeutic products gave the go-ahead for a Phase I/II clinical trial on chronic spinal cord injury at the Balgrist University Hospital in Zurich, Switzerland. The trial uses a type of stem cell developed by the company Stem Cells Inc. The cells are known as human central nervous system stem cells, or HuCNS-SC, and are derived from human brain tissue. HuCNS-SC cells can make any of the three major kinds of neural cells found in the central nervous system. In the trial, HuCNS-SC cells will be transplanted into the spinal cord of patients at least six weeks after injury.
Phase and objective: This is a phase I/II trial to evaluate the safety of transplanting HuCNS-SC cells into the spine of patients with chronic spinal injury.
Dates: March 2011–March 2016.
Enrollment status: Recruiting. Aims to enroll 12 patients.
More information on this study
California-based biotech company Geron also had a widely-reported clinical trial under way for a human embryonic stem cell-based therapy. In November 2011 Geron announced it was halting this trial to focus on other areas of research.
Other studies have shown that cells in the lining of the nasal cavity help regenerate spinal injuries when transplanted into the spinal cords of injured rats. Researchers would like to transfer this approach to patients with a specific type of spinal cord injury, called brachial plexus avulsion. In this type of injury, which occurs most commonly in motorcycle accidents, the nerves of the arm are separated from the spinal cord, resulting in paralysis of the arm.
Relevant links:
Professor Geoffrey Raisman's research page - using cells in the lining of the nasal cavity for spinal cord regeneration
The National Institute of Neurological Disorders and Stroke
European Spinal Cord Injury Federation
Increasingly, advances in spinal cord injury (SCI) research are finding their way into clinical practice. Many experimental therapies, some of which involve stem cells, are currently undergoing clinical trials or are preparing to enter the clinical trial phase of their development. To help those considering participation in a clinical trial, a panel of researchers and doctors with extensive experience in SCI have, though the ICCP (International Campaign for Cures for spinal cord injury Paralysis), developed an easy-to-read 40-page guide for people with spinal cord injury, their families, friends and caregivers.
This booklet, Experimental Treatments for Spinal Cord Injuries: What you should know if you are considering participation in a clinical trial, is freely available for download in English, French, Spanish, German, Turkish, Japanese and Chinese from the ICORD website.
